Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126663783 | 12666378 | 3 | F | 20160816 | 20160906 | 20160818 | 20160908 | EXP | EC-ABBVIE-16P-047-1703208-00 | ABBVIE | 16.49 | YR | M | Y | 49.00000 | KG | 20160908 | CN | COUNTRY NOT SPECIFIED | EC |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126663783 | 12666378 | 1 | PS | ZEMPLAR | PARICALCITOL | 1 | Intravenous (not otherwise specified) | UNKNOWN | 20819 | 5 | UG | SOLUTION FOR INJECTION | |||||||
| 126663783 | 12666378 | 2 | C | ENALAPRIL | ENALAPRIL | 1 | Unknown | 0 | |||||||||||
| 126663783 | 12666378 | 3 | C | CARVEDILOL. | CARVEDILOL | 1 | Unknown | 0 | |||||||||||
| 126663783 | 12666378 | 4 | C | AMLODIPINE | AMLODIPINE BESYLATE | 1 | Unknown | 0 | |||||||||||
| 126663783 | 12666378 | 5 | C | LOSARTAN. | LOSARTAN | 1 | Unknown | 0 | |||||||||||
| 126663783 | 12666378 | 6 | C | VITAMIN B COMPLEX | CYANOCOBALAMINDEXPANTHENOLNIACINAMIDEPYRIDOXINE HYDROCHLORIDERIBOFLAVIN 5'-PHOSPHATE SODIUMTHIAMINE HYDROCHLORIDEVITAMIN B COMPLEX | 1 | Unknown | 0 | |||||||||||
| 126663783 | 12666378 | 7 | C | VITAMIN C | ASCORBIC ACID | 1 | Unknown | 0 | |||||||||||
| 126663783 | 12666378 | 8 | C | FOLIC ACID. | FOLIC ACID | 1 | Unknown | 0 | |||||||||||
| 126663783 | 12666378 | 9 | C | SIMVASTATIN. | SIMVASTATIN | 1 | Unknown | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126663783 | 12666378 | 1 | Hyperparathyroidism secondary |
| 126663783 | 12666378 | 2 | Product used for unknown indication |
| 126663783 | 12666378 | 3 | Product used for unknown indication |
| 126663783 | 12666378 | 4 | Product used for unknown indication |
| 126663783 | 12666378 | 5 | Product used for unknown indication |
| 126663783 | 12666378 | 6 | Product used for unknown indication |
| 126663783 | 12666378 | 7 | Product used for unknown indication |
| 126663783 | 12666378 | 8 | Product used for unknown indication |
| 126663783 | 12666378 | 9 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126663783 | 12666378 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126663783 | 12666378 | Blood parathyroid hormone abnormal | |
| 126663783 | 12666378 | Blood phosphorus abnormal | |
| 126663783 | 12666378 | Blood pressure increased | |
| 126663783 | 12666378 | Dizziness | |
| 126663783 | 12666378 | Dyspnoea | |
| 126663783 | 12666378 | Fatigue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126663783 | 12666378 | 1 | 20151202 | 20160226 | 0 |